Advertisement

Topics

STAT Plus: Lilly takes a stab at pricing transparency, but is it enough of the right data?

11:00 EDT 20 Mar 2017 | STAT

Average discounts off list prices rose to 50 percent from 28 percent over the past five years and Lilly maintained increases in net prices were 2.4 percent.

Original Article: STAT Plus: Lilly takes a stab at pricing transparency, but is it enough of the right data?

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Lilly takes a stab at pricing transparency, but is it enough of the right data?"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...